Replies to post #217668 on Biotech Values

[kris_kade]

Good that Sakura-3 is open label; so investors can track any safety issue.

The long trials that Revance has gone thru speaks loud as how high the bar is when it comes to ‘Botox’ approval.

I just hope they keep their laser focus on getting BLA filed as quickly as possible. Execution, execution and execution. Biosimilars can wait.